WAVE Life Sciences (WVE) no longer intends to offers ordinary shares
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
B.Riley Reiterates Buy Rating on WAVE Life Sciences (WVE)
September 25, 2024 6:24 AM EDTB.Riley analyst Madison El-Saadi reiterated a Buy rating and $11.00 price target on WAVE Life Sciences (NASDAQ: WVE).
The analyst comments "In totality, we believe results exceeded our/investor expectations (9/18 initiation) and replicated the preclinical and early clinical datasets indicative of best-in-class exon skipping profile... More
